glp 1 patient information Dietary intake by patients taking GLP-1 and dual GIP/GLP-1 receptor agonists: A narrative review and discussion of research needs Poll: 1 in 8 Adults

Small studies in lupus patients on GLP-1 therapy have suggested fewer flares and possible protection against progression to kidney disease in lupus nephritis

[DOI] [PMC free article] [PubMed] [Google Scholar] 116.US Department of Health and Human Services

All individuals were provided lifestyle counseling and randomized (flip of a coin) to receive either Wegovy or a matching placebo (a substance that has no therapeutic effect) for a total of 68 weeks

Wish the subscription options were clearer, but overall great experience

Fernando Ovalle, an obesity medicine specialist, told Drugwatch

For further information on the safety of this medication, please refer to the patient information leaflet